Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARKERVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARKERVISION's regulatory disclosures and financial reporting.
ParkerVision, Inc. reported a planned change on its board of directors. On May 15, 2026, longtime director Lewis Titterton retired and resigned from the Board and from the Audit and Compensation Committees, with the company stating his departure was not due to any disagreement over operations, policies, or practices.
On May 19, 2026, the Board unanimously appointed Anthony (Tony) Bowers, age 69, as a Class II director to fill the vacancy and named him to the Audit and Compensation Committees. Bowers is Director of Corporate Sales at Intro-act, LLC and has over 30 years of corporate and institutional sales experience, including leadership roles at OTR Global and Goldman Sachs, and holds degrees from the Wharton School and Amherst College.
The company notes there are no special arrangements under which Bowers was selected, and no related-party transactions requiring disclosure. He will receive ParkerVision’s standard non-employee director compensation and has signed the company’s standard indemnification agreement. A press release announcing these changes was furnished as an exhibit.
ParkerVision Inc. Schedule 13G/A: Gem Investment Advisors and affiliates report beneficial ownership of 15,181,550 shares, representing 9.99% of Common Stock. The filing shows shared voting and dispositive power across Gem Investment Advisors, GEM PARTNERS (12,797,379 shares) and Flat Rock Partners (2,377,571 shares).
ParkerVision, Inc. registers 9,387,500 shares of Common Stock for resale by selling shareholders as set forth in the prospectus supplement dated May 7, 2026.
The prospectus supplement states the company will not receive proceeds from resales by the selling shareholders; if the 200,000 Options are exercised for cash, the company would receive up to $42,620 in gross proceeds to be used for general working capital purposes. As of May 1, 2026, 147,767,649 shares of common stock were outstanding.
ParkerVision, Inc. registers the resale of up to 16,638,353 shares of Common Stock issuable upon conversion of convertible promissory notes with a fixed conversion price of $0.13 per share. This supplement attaches the company's Form 10-Q filed May 7, 2026.
The 10-Q shows cash and cash equivalents of $3.4 million, an accumulated deficit of $457.2 million, and a secured contingent payment obligation measured at fair value of $40.1 million. Shares outstanding were 147,767,649 as of May 1, 2026. The 10-Q also discloses substantial doubt about the company’s ability to continue as a going concern for the next twelve months.
ParkerVision, Inc. files a prospectus supplement registering 1,578,946 shares of common stock for resale by a selling stockholder. The registration covers 1,052,631 shares and 526,315 shares underlying warrants issued under a December 14, 2021 agreement. The company will not receive proceeds from the resale; however, if the 526,315 Warrants are exercised for cash, the company would receive up to $526,315 in gross proceeds to be used for general working capital, including litigation expenses. Shares outstanding were 147,767,649 as of May 1, 2026. This supplement updates the prospectus with the company’s Form 10-Q for the quarter ended March 31, 2026.
ParkerVision, Inc. filed a Prospectus Supplement dated May 7, 2026 registering the resale of 13,342,953 shares of Common Stock under a prior prospectus. The supplement states the company will not receive proceeds from sales by the selling stockholders; however, if underlying warrants are exercised for cash, the company would receive up to $2,833,756 in gross proceeds.
The supplement attaches the company’s Form 10-Q for the quarter ended March 31, 2026, which shows cash of $3.4 million, a net loss for the quarter of $1.553 million, and total secured contingent payment obligations measured at fair value of $40.144 million. Shares outstanding were 147,767,649 as of May 1, 2026. The filing reiterates substantial litigation-driven operations, contingent payment obligations tied to patent proceeds, and management’s statement of substantial doubt about going concern for the next year.
ParkerVision, Inc. files a Prospectus Supplement registering 5,871,584 shares of common stock for resale by selling stockholders. The supplement attaches ParkerVision’s Form 10-Q for the quarter ended March 31, 2026 and states the company will not receive proceeds from these resales.
The Form 10-Q shows $3.4 million in cash, a net loss of $1.553 million for the three months ended March 31, 2026, secured contingent payment obligations of $40.144 million, and 147,767,649 shares outstanding as of May 1, 2026. The filing discloses substantial doubt about the company’s ability to continue as a going concern for one year.
ParkerVision, Inc. filed a Prospectus Supplement dated May 7, 2026 registering 16,809,295 shares of Common Stock for resale by selling stockholders. The registration covers listed conversion shares, private-offering issuances, shares issued for services/repayments, and up to warrants exercisable for up to 5,200,000 shares.
The company will not receive proceeds from resales by selling stockholders; however, it would receive up to $3,900,000 if the Aspire and Tailwinds warrants are exercised for cash. The supplement incorporates ParkerVision’s Form 10-Q for the quarter ended March 31, 2026, which shows cash of $3.4M, an accumulated deficit of $457.2M, a secured contingent payment obligation measured at $40.144M, and shares outstanding of 147,767,649 as of May 1, 2026. The 10-Q also discloses substantial doubt about the company’s ability to continue as a going concern for one year.
ParkerVision, Inc. files a Prospectus Supplement registering 18,014,164 shares of common stock for resale by selling stockholders, as described in the Prospectus Supplement dated May 7, 2026. The registration covers (i) up to 5,457,583 shares issuable upon conversion of Tranche 1 Notes at a fixed conversion price of $0.10 per share, (ii) up to 10,131,581 shares issuable upon conversion of Tranche 2 Notes at a fixed conversion price of $0.08 per share, (iii) up to 625,000 shares issued for services under the Fisher Consulting Agreement, and (iv) up to 1,800,000 shares issuable upon exercise of a five-year Park Consulting Warrant with an exercise price of $0.10 per share. The company will not receive proceeds from sales by the selling stockholders; however, if the Park Consulting Warrant is exercised for cash, ParkerVision would receive up to $180,000 in gross proceeds.
Context: shares outstanding were 147,767,649 as of May 1, 2026. The supplement attaches the registrant's Form 10-Q for the quarter ended March 31, 2026.
ParkerVision filed a Prospectus Supplement registering 17,189,660 shares of common stock for resale by selling stockholders under previously filed registration statements. The supplement attaches the company's Form 10-Q for the quarter ended March 31, 2026 and notes that the company will not receive proceeds from selling stockholders' resales. The company may receive proceeds only if certain warrants are exercised (including up to $700,000 from the 2016 Warrant and potential proceeds related to the Aspire PIPE arrangements); any proceeds received are expected to be used to fund patent enforcement actions and for working capital.